Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme

This publication has 41 references indexed in Scilit:

• A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting
  Molecular Therapy, 2004
• Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
  Expert Opinion on Biological Therapy, 2004
• Viral Shedding and Biodistribution of G207, a MuItimutated, Conditionally Replicating Herpes Simplex Virus Type 1, after Intracerebral Inoculation in Aotus
  Molecular Therapy, 2000
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
  British Journal of Cancer, 2000
• Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity
  The Journal of Experimental Medicine, 2000
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991
  Journal of Neurosurgery, 1998
• Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-κB
  International Immunology, 1996
• The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1995
• Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy
  JNCI Journal of the National Cancer Institute, 1994